Arch Biopartners Inc.

C$0.94As of Sun 8 Nov 2026, 12:00 UTC

TSXV:ARCHHealthcare

Country Canada

PE (Fwd) —

TSR 10Y CAGR 7.39%

Div yield —

ROE —

Biotechnology

Beta (5Y) 1.61

PE TTM —

TSR TTM (5.05%)

Mkt cap C$63.86M

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

$1.01

—

7.80%

—

TTM

FYE 30 Sep CAD

FY2022

FY2023

FY2024

FY2025

FY2026E

FY2027E

Trend

10Y

Peers

◌—

Revenue$M

—

◌—

—

Revenue growth%

—

Gross margin%

—

Operating margin%

—

Net margin%

—

P/E ratio (avg)x

—

EV/EBITx

—

(2.72)

FCF yield (avg)%

—

0.21

(0.18)

(2.26)

(1.45)

—

(0.82)

—

FCF margin%

—

0.614

FCF / Net incomex

—

(0.341)

0.070

0.595

1.020

—

0.333

—

ROIC%

—

Return on equity%

—

(4937.88)

Return on assets%

—

(226.47)

(284.05)

(419.01)

(1485.45)

—

(351.53)

—

(0.04)

EPS$

—

(0.02)

(0.05)

(0.06)

(0.02)

—

EPS growth%

—

(135.14)

(16.14)

61.73

—

(16.14)

—

(0.06)

Bookvalue per sh$

—

(0.07)

(0.09)

(0.07)

(0.06)

—

(0.03)

FCF per share$

—

0.01

—

(0.04)

(0.02)

—

Dividend per sh$

—

Div yield (avg)%

—

Payout ratio%

—

67.93

Shares (diluted)M

—

62.16

62.47

63.38

65.60

◌65.60

1.81%

—

Buyback yield%

—

(0.49)

(1.46)

(3.51)

◌—

(1.46)

—

(0.650)

D/E ratiox

—

(0.987)

(0.910)

(0.637)

(0.643)

(0.650)

(0.777)

—

66.45

Enterprise value$M

—

227.4

130.7

106.0

111.5

64.26

(21.14%)

—

LT debt$M

—

2.313

0.704

—

(69.56%)

—

Peers (US$42.03M)

Cap (US$)

Helix BioPharma Corp.

48.66M

—

ProMIS Neurosciences…

37.31M

—

BriaCell Therapeutics…

34.43M

—

Apollomics, Inc.

41.72M

—

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(11.05)

(6.579)

Own earn%

—

Sh yield%

—

(1.46)

Owners

Insiders/Inst%

20.91

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/4

Revenue growth years

—

EPS growth years

1/3

Dividend streakyrs

Op margin range%

—

$1 testx

—

Incr. ROIC%

—

Arch Biopartners Inc., together with its subsidiaries, engages in the development of novel drugs for acute kidney injury and organ damage in Canada.

Revenue by segment

No breakdown available

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available